We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The generic industry’s image has not suffered despite a number of recent warning letters to companies, according to William Marth, president and CEO of Teva Pharmaceutical Industries’ North American unit.